Cooperative Agreement HT9425262E001
Award Date 9/30/26
Completion Date 9/29/30
Dollars Obligated $11M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
New York, NY 10065, USA
Similar Awards
- Federal Cooperative Agreement Summary The Defense Health Agency (DHA) awarded a $19.1 million Cooperative Agreement to The University of Texas MD Anderson Cancer Center for the Convergent Science Cancer Consortium for Immune Cell Engineering, effective August 1, 2025 through July 31, 2029. This award falls under the Military Medical Research and Development program (CFDA 12.420), which supports advanced biomedical research to transform healthcare for military service members, veterans, and the...
- Summary of Federal Cooperative Agreement Award H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. received a $18.7 million Cooperative Agreement from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 1, 2025, with a completion date of August 31, 2029. The award funds a four-year research initiative focused on developing and evaluating combinatorial therapies utilizing dendritic cell therapies to...
- The Defense Health Agency awarded a $619,500 Project Grant to the Sloan-Kettering Institute for Cancer Research, a non-profit organization in New York, NY. The grant is funded through the Military Medical Research and Development (CFDA 12.420) program and will support research to investigate the immunogenicity and targeting of shared neoantigens in adenoid cystic cancer over a 3-year period from September 1, 2023 to August 31, 2026. The research aims to transform health care for Service...
- Summary of Federal Cooperative Agreement Award Vanderbilt University Medical Center (VUMC) received a $5.67 million Cooperative Agreement from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the Convergent Science Cancer Consortium for Immune Cell Engineering. The four-year award, effective August 1, 2025, through July 31, 2029, supports advanced biomedical research aimed at advancing cancer treatment through innovative immune cell...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $1,145,096 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the project "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy." The award was issued on July 1, 2026, with a completion date of June 30, 2029. This three-year research initiative will be conducted at the Institute's facility in New York, NY....
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute For Cancer Research a $533,308 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2029. The award funds research titled "Integrated Immunomodulatory Analysis of LAG3 Inhibition in Renal Cell Carcinoma," which investigates lymphocyte-activation gene 3 (LAG3) checkpoint inhibition as a therapeutic...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Project Grant Award Summary The Sloan-Kettering Institute for Cancer Research received a $604,902 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2026 through June 30, 2029. The award funds research titled "Modeling and Targeting FH-Deficient Renal Cell Carcinoma for Precision Therapy," which focuses on developing targeted therapeutic approaches for a specific subset of...
- Federal Grant Award Summary The Defense Health Agency awarded Sloan-Kettering Institute for Cancer Research $1,108,654 under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, for a four-year project titled "Accelerating Global Research for Relapsed or Refractory Extracranial Malignant Germ Cell Tumors" (completion date: September 29, 2029). The project delivers research and development services focused on advancing clinical care and...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded Sloan-Kettering Institute for Cancer Research a $750,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective October 1, 2026, through April 30, 2029. The award supports research titled "Eliminating TREX1 to Restore Immune Control in Triple-Negative Breast Cancer," which focuses on investigating immunological mechanisms in breast cancer treatment. This research...